Danish biotechnology firm Orphazyme, which develops medication for rare diseases, forecasts an operating deficit at DKK 100m-150m (USD 16.2m-24.2m) in 2021, which is significantly lower than the realized deficit for 2020 at DKK 608m, according to the firm's 2020 annual report.
"We expect 2021 to be a transformational year for Orphazyme with the anticipated approval and launch of arimoclomol in NPC (Niemann-Pick type C, -ed.) and two key readouts from our late-stage clinical trials in IBM (inclusion body myositis, -ed.) and ALS (amyotrophic lateral sclerosis, -ed.)," the firm writes in the report.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers.
Start a free company trial todayMore from MedWatch
Ambu board had started headhunting process long before firing of CEO
Thursday’s CEO change had been in the works for a while, says Ambu’s board chair Jørgen Jensen.
Nine new drugs recommended for approval by CHMP at May meeting
During this month’s meeting of the CHMP, the EMA’s expert committee, a total of nine new drugs have been recommended while six drugs have had indication extensions accepted. Two treatments have been rejected.
Britt Meelby Jensen wants to rebuild trust in Ambu
After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.
Outgoing Ambu CEO commends colleagues
”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.
Top news from MedWatch this week
Miss anything?
KLIFO is looking for a Clinical Supply Manager for our Glostrup office 
Cell Culture Scientist/Senior Scientist 
Quality System Manager 
Director Global Engineering 
Project Manager & Scrum Master 
Consultant Manager 
CMO Operations Specialist - screening & selection of CMO/CDMO’s 
Director for innovative pre-clinical testing unit 
SAP System Specialist (Product Supply) – Business Application Services 
Procurement Process Excellence Specialist 
Senior Manager, Clinical Trial Budget 
Client Talent Acquisition Specialist 
Account Manager 
Clinical Project Manager 
Key Account Manager, Europe and Asia